Gilead and Galapagos NV’s Filgotinib (JAK1i) Achieves Primary Endpoints for P-II TORTUGA study in AS patients

 Gilead and Galapagos NV’s Filgotinib (JAK1i) Achieves Primary Endpoints for P-II TORTUGA study in AS patients

Shots:

  • The P-II TORTUGA study is assessing safety and efficacy in moderate to severe ankylosing spondylitis (AS) adults in ratio of 1:1 administering filgotinib 200 mg or PBO qw for 12 wks.
  • TORTUGA results (N=116): improvement in AS disease, ASAS20 response (76% vs 40%), ASDAS (-1.5 vs -0.6) with no new safety signals and deaths observed in study
  • TORTUGA study was conducted in Belgium, Bulgaria, Czech Republic, Estonia, Poland, Spain and Ukraine. Additionally, Filgotinib is being assessed in RA (FINCH P-III), CD (SELECTION P-III) UC

Click here to read full press release/ article | Ref: Gilead | Image: Wall Street

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post